Greek NIS Spiolto ELLACTO

NCT03419962 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1360

Last updated 2020-04-27

Study results available
· View outcomes & findings →

Summary

Open-label observational study: including COPD patients receiving treatment with Spiolto® Respimat® for approximately 6 weeks, which is the average time between two medical consultations

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

MaxSpiolto® Respimat® 160 Characters...

as per the approved SmPC

Sponsors & Collaborators

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-19
Primary Completion
2018-11-09
Completion
2019-04-03

Countries

  • Greece

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03419962 on ClinicalTrials.gov